High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Published on Jun 1, 2017in Cancer Discovery26.37
· DOI :10.1158/2159-8290.CD-16-1396
Christophe Massard43
Estimated H-index: 43
(Université Paris-Saclay),
Stefan Michiels50
Estimated H-index: 50
(Université Paris-Saclay)
+ 30 AuthorsJean-Charles Soria79
Estimated H-index: 79
(Université Paris-Saclay)
High-throughput genomic analyses may improve outcomes in patients with advanced cancers. MOSCATO 01 is a prospective clinical trial evaluating the clinical benefit of this approach. Nucleic acids were extracted from fresh-frozen tumor biopsies and analyzed by array comparative genomic hybridization, next-generation sequencing, and RNA sequencing. The primary objective was to evaluate clinical benefit as measured by the percentage of patients presenting progression-free survival (PFS) on matched therapy (PFS2) 1.3-fold longer than the PFS on prior therapy (PFS1). A total of 1,035 adult patients were included, and a biopsy was performed in 948. An actionable molecular alteration was identified in 411 of 843 patients with a molecular portrait. A total of 199 patients were treated with a targeted therapy matched to a genomic alteration. The PFS2/PFS1 ratio was >1.3 in 33% of the patients (63/193). Objective responses were observed in 22 of 194 patients (11%; 95% CI, 7%–17%), and median overall survival was 11.9 months (95% CI, 9.5–14.3 months). Significance: This study suggests that high-throughput genomics could improve outcomes in a subset of patients with hard-to-treat cancers. Although these results are encouraging, only 7% of the successfully screened patients benefited from this approach. Randomized trials are needed to validate this hypothesis and to quantify the magnitude of benefit. Expanding drug access could increase the percentage of patients who benefit. Cancer Discov; 7(6); 586–95. ©2017 AACR. See related commentary by Schram and Hyman, p. 552 . This article is highlighted in the In This Issue feature, p. 539
  • References (31)
  • Citations (130)
#1Charles Swanton (Francis Crick Institute)H-Index: 66
#2Jean-Charles Soria (French Institute of Health and Medical Research)H-Index: 79
Last.Fabrice Andre (French Institute of Health and Medical Research)H-Index: 78
view all 19 authors...
40 CitationsSource
#1Jennifer J. Wheler (University of Texas MD Anderson Cancer Center)H-Index: 32
#2Filip JankuH-Index: 41
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 19 authors...
71 CitationsSource
#1Fabrice Andre (Institut Gustave Roussy)H-Index: 78
#2Sara A. Hurvitz (UCLA: University of California, Los Angeles)H-Index: 34
Last.Dennis J. Slamon (UCLA: University of California, Los Angeles)H-Index: 98
view all 16 authors...
68 CitationsSource
#1Gabriel N. Hortobagyi (University of Texas MD Anderson Cancer Center)H-Index: 146
#2David Chen (Novartis)H-Index: 16
Last.José Baselga (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 137
view all 25 authors...
87 CitationsSource
#1S. Postel-VinayH-Index: 5
#2Yannick Boursin (French Institute of Health and Medical Research)H-Index: 2
Last.J.C. SoriaH-Index: 19
view all 14 authors...
7 CitationsSource
#1Christophe Le Tourneau (Curie Institute)H-Index: 25
#2Jean-Pierre DelordH-Index: 31
Last.Xavier Paoletti (Curie Institute)H-Index: 32
view all 23 authors...
374 CitationsSource
#1Funda Meric-Bernstam (University of Texas MD Anderson Cancer Center)H-Index: 76
#2Lauren Brusco (University of Texas MD Anderson Cancer Center)H-Index: 6
Last.Gordon B. Mills (University of Texas MD Anderson Cancer Center)H-Index: 151
view all 19 authors...
180 CitationsSource
#1David M. Hyman (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 35
#2Igor Puzanov (Vandy: Vanderbilt University)H-Index: 52
Last.José Baselga (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 137
view all 23 authors...
604 CitationsSource
#1Himisha Beltran (Cornell University)H-Index: 40
#2Kenneth Eng (Cornell University)H-Index: 8
Last.Mark Raffeld (Cornell University)H-Index: 146
view all 44 authors...
122 CitationsSource
#1Fabrice Andre (French Institute of Health and Medical Research)H-Index: 78
#2Elaine R. Mardis (WashU: Washington University in St. Louis)H-Index: 131
Last.Charles Swanton (London Research Institute)H-Index: 66
view all 6 authors...
63 CitationsSource
Cited By130
#1Birgitte BertelsenH-Index: 9
#2Ida Viller TuxenH-Index: 3
Last.Finn Cilius NielsenH-Index: 55
view all 14 authors...
#1Takahiko Koyama (IBM)H-Index: 3
#2Kahn Rhrissorrakrai (IBM)H-Index: 11
Last.Laxmi Parida (IBM)H-Index: 22
view all 3 authors...
#1Anja van de Stolpe (Philips)H-Index: 11
#2Laurent Holtzer (Philips)H-Index: 1
Last.Wim F. J. Verhaegh (Philips)H-Index: 15
view all 5 authors...
3 CitationsSource
#2Sheldon X Kong (Bayer AG: Bayer HealthCare Pharmaceuticals)
view all 6 authors...
#1Teemu D. Laajala (Anschutz Medical Campus)
#2Travis GerkeH-Index: 10
Last.James C. Costello (Anschutz Medical Campus)H-Index: 20
view all 4 authors...
#1C. Benedikt Westphalen (LMU: Ludwig Maximilian University of Munich)H-Index: 9
#2Moritz Jesinghaus (TUM: Technische Universität München)H-Index: 11
Last.Wilko Weichert (TUM: Technische Universität München)H-Index: 52
view all 9 authors...
#1D L van der Velden (NKI-AVL: Netherlands Cancer Institute)H-Index: 2
#2L Hoes (NKI-AVL: Netherlands Cancer Institute)H-Index: 1
Last.Emile E. Voest (NKI-AVL: Netherlands Cancer Institute)H-Index: 48
view all 27 authors...
2 CitationsSource
#1Johannes Doescher (University of Ulm)H-Index: 6
#2Stephanie E Weissinger (University of Ulm)H-Index: 6
Last.Patrick J. Schuler (University of Ulm)H-Index: 20
view all 13 authors...
View next paperMolecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.